Microsatellite (MS) status is also a stratification factor for CRC-PM patients undergoing CRS/HIPEC, with MSI having a better prognosis [34,40], which may be one of the reasons for the differences between KRAS and BRAF in different studies. The gene discussed is KRAS; the disease is colorectal carcinoma.